Business Context and Reporting Period
This Form 8-K Current Report was filed by Liminatus Pharma, Inc. (Nasdaq: LIMN, LIMNW) on July 29, 2026. The Company is an emerging growth company incorporated in Delaware. The filing addresses a material event under Item 8.01 regarding the Company's stockholders' equity status following a previously announced merger with InnocsAI LLC.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The only quantitative financial metric disclosed is the Company's belief that its stockholders' equity now exceeds $2.5 million as a result of the merger transaction.
Material Changes
- Stockholders' Equity: The Company reports that its stockholders' equity has increased to over $2.5 million due to the merger with InnocsAI LLC.
- Listing Status: The Company is currently awaiting a compliance determination from The Nasdaq Stock Market LLC regarding its stockholders' equity requirement.
Outlook, Risks, and Management Commentary
Management states that even if Nasdaq determines the Company is currently in compliance, the exchange will continue to monitor ongoing compliance. If the Company fails to evidence compliance in its next periodic report, it may be subject to future delisting. The filing includes standard forward-looking statements warning that there is no assurance Nasdaq will accept the Company's plan to regain compliance or that the Company will meet continued listing standards in the future.
Investor Verification Checklist
- Verify the official compliance determination letter from Nasdaq regarding the $2.5 million stockholders' equity threshold.
- Confirm the final closing details and financial impact of the merger with InnocsAI LLC.
- Monitor upcoming periodic reports (10-Q or 10-K) to ensure continued compliance with Nasdaq listing standards.
- Review the Company's full SEC filings for detailed risk factors related to potential delisting.